MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-05-2026
National Research Corporation Net Debt 2011-2026 | NRC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.3 M | 54.2 M | 30.1 M | -2.71 M | -27.7 M | -8.14 M | 20.7 M | 24.9 M | -33.6 M | -29.5 M | -36.4 M | -32 M | -11.8 M | 4.48 M | 6.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.3 M | -36.4 M | 2.02 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.24 B | $ 114.84 | -0.55 % | $ 34.9 B |  USA |
 |
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.59 | 1.37 % | $ 84.1 K | USA |
|
Biodesix
BDSX
|
14.5 M | $ 15.32 | 1.66 % | $ 1.99 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
1.19 M | $ 1.19 | -1.25 % | $ 6.48 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 16.57 | 2.28 % | $ 178 M | China |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 18.37 | 0.33 % | $ 979 M | USA |
 |
Celcuity
CELC
|
-28.1 M | $ 113.92 | 1.14 % | $ 5.33 B | USA |
 |
Co-Diagnostics
CODX
|
-10.6 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 167.82 | -3.49 % | $ 8.32 B | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 24.95 | 0.44 % | $ 693 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 198.98 | 0.92 % | $ 22.1 B | USA |
 |
Danaher Corporation
DHR
|
14 B | $ 191.91 | 0.41 % | $ 137 B | USA |
 |
DexCom
DXCM
|
-842 M | $ 63.19 | 1.56 % | $ 24.7 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 16.66 | -0.95 % | $ 504 M | USA |
 |
Guardant Health
GH
|
1.15 B | $ 90.61 | -3.44 % | $ 11.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 111.56 | -2.31 % | $ 9.2 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.96 | 5.82 % | $ 8.67 M | USA |
 |
Illumina
ILMN
|
-494 M | $ 128.04 | 0.52 % | $ 20.4 B | USA |
 |
IQVIA Holdings
IQV
|
12 B | $ 171.32 | -1.12 % | $ 29.4 B | USA |
 |
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 275.75 | 0.74 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
213 M | $ 76.36 | 0.35 % | $ 5.15 B | USA |
 |
Medpace Holdings
MEDP
|
-360 M | $ 490.0 | -1.67 % | $ 14.1 B | USA |
 |
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | USA |
 |
Mettler-Toledo International
MTD
|
2.06 B | $ 1 257.33 | -0.21 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.78 | 0.63 % | $ 443 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-270 K | $ 4.51 | -3.84 % | $ 3.55 M | USA |
 |
NeoGenomics
NEO
|
187 M | $ 8.0 | - | $ 1.02 B | USA |